This article was originally published in The Gray Sheet
Executive SummaryFiles 510(k) application for its QuickVue one-step fecal occult blood test. Quidel maintains that the two-minute test has "improved specificity and sensitivity over the most widely used tests which employ guaiac-based chemistry." Accuracy of guaiac-based tests is affected by patient noncompliance with dietary restrictions that must be followed for two days prior to testing. "The QuickVue FOB test circumvents the dietary restrictions and compliance problems...because it is very specific for human hemoglobin found only in human red blood cells," Quidel says.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.